![Brett Carter](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Brett Carter
Directeur/Membre du Conseil chez
AMPLIA THERAPEUTICS LIMITED
Profil
Brett Carter is currently a Non-Executive Director at Amplia Therapeutics Ltd. since 2026.
Mr. Carter is also a Director at Grey Wolf Therapeutics Ltd. and the Chief Operating Officer at Medicines Development for Global Health Ltd. Mr. Carter completed an MBA at London Business School and holds an undergraduate degree from RMIT University.
Postes actifs de Brett Carter
| Sociétés | Poste | Début |
|---|---|---|
| AMPLIA THERAPEUTICS LIMITED | Directeur/Membre du Conseil | 06/07/2026 |
Medicines Development for Global Health Ltd
 Medicines Development for Global Health Ltd Pharmaceuticals: MajorHealth Technology Develops medicines and vaccines | Directeur des opérations | - |
Grey Wolf Therapeutics Ltd.
 Grey Wolf Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops next generation immuno-oncology drugs | Directeur/Membre du Conseil | - |
Formation de Brett Carter
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
24
Relations au 1er degré
5
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
RMIT University
 RMIT University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
London Business School
 London Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Medicines Development for Global Health Ltd
Medicines Development for Global Health Ltd Pharmaceuticals: MajorHealth Technology Develops medicines and vaccines | Health Technology |
Amplia Therapeutics Ltd.
 Amplia Therapeutics Ltd. BiotechnologyHealth Technology Develops drug candidates for oncology and chronic fibrosis | Health Technology |
Grey Wolf Therapeutics Ltd.
Grey Wolf Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops next generation immuno-oncology drugs | Health Technology |
